XLON
ANP
Market cap109mUSD
Oct 09, Last price
510.00GBP
1D
0.00%
1Q
-3.77%
Jan 2017
76.78%
IPO
101.58%
Name
Anpario PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Anpario plc, together with its subsidiaries, manufactures and distributes natural animal feed additives for animal health, nutrition, and biosecurity. Its health and performance category offers various products that support and maintain animal gut health, including phytogenic and acid based eubiotics, and omega fatty acids under the Orego-Stim, Optomega, pHorce, Salkil, and Genex brands; and feed quality category provides products, such as enzymes, antioxidants, pellet binders, mould inhibitors, and acid based eubiotics under the pHorce, Feedzyme, Salgard, Oxigard, Moldgard, and Mastercube brands. The company's hygiene and insect control category contain products comprising water sanitation tablets, 100% natural insect control powders, and natural drying agents that minimizes the environmental microbial burden, supports the gut health, and animal performance under the Credence, Mitex, and Clean & Dry brands; and toxin management category products consisting of mycotoxin binders under the Anpro brand. It has operations in the Americas, Asia, Europe, the Middle East, and Africa. The company was formerly known as Kiotech International plc and changed its name to Anpario plc in November 2011. Anpario plc was founded in 1996 and is headquartered in Worksop, the United Kingdom.
Key people
Non-Executive Chairman of the Board
Richard P. Edwards
Chief Executive Officer, Executive Vice Chairman of the Board · since 2016
Karen L. Prior
Finance Director, Company Secretary, Executive Director · since 2012
Richard Wood
Non-Executive Director · since 2017
Headquarters & legal address
UNIT 5
MANTON WOOD ENTERPRISE PARK
WORKSOP, NTT S80 2RS
GB
MANTON WOOD ENTERPRISE PARK
WORKSOP, NTT S80 2RS
GB
Previous name
KIOTECH INTERNATIONAL PLC
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||